2:30 PM
 | 
May 30, 2019
 |  BC Extra  |  Company News

Epizyme looks to sarcoma for first approval

More than a decade after it was founded and after nearly $1 billion raised, Epizyme has submitted its first NDA to FDA for a small molecule inhibitor of an epigenetic cancer target. The company is seeking accelerated approval of EZH2 inhibitor tazemetostat to treat metastatic or locally advanced epithelioid sarcoma in patients not eligible for curative surgery

Epizyme Inc. (NASDAQ:EPZM) plans to submit in 4Q19 a second NDA to FDA for tazemetostat to treat follicular lymphoma.

The sarcoma submission was based on updated data from 62...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >